Profil
Alexander Levitzki is the founder of TK-Signal Ltd. (founded in 2001) and NovoTyr Therapeutics Ltd. (founded in 2005).
He held the title of Chief Scientific Officer at TK-Signal Ltd. and Director & Chief Scientific Officer at NovoTyr Therapeutics Ltd. Dr. Levitzki is currently the Director at The Institute for Advanced Studies In Aging & Geriatric Medi, Director at Targimmune Therapeutics AG, Professor at The Hebrew University of Jerusalem (since 1977), and Member at Israel Academy of Sciences & Humanities.
He previously held the position of Director at BioCancell Therapeutics, Inc. and Director at Quinova Rx Ltd.
Aktive Positionen von Alexander Levitzki
| Unternehmen | Position | Beginn |
|---|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1977 |
The Institute for Advanced Studies In Aging & Geriatric Medi | Direktor/Vorstandsmitglied | - |
Israel Academy of Sciences & Humanities
Israel Academy of Sciences & Humanities Miscellaneous Commercial ServicesCommercial Services Operates as sciences and humanities academy | Corporate Officer/Principal | - |
Targimmune Therapeutics AG
Targimmune Therapeutics AG BiotechnologyHealth Technology Develops novel targeted oncology immunotherapies | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Alexander Levitzki
| Unternehmen | Position | Ende |
|---|---|---|
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology Is a biopharmaceuticals company | Direktor/Vorstandsmitglied | 15.11.2009 |
TK-Signal Ltd.
TK-Signal Ltd. Medical SpecialtiesHealth Technology Develops therapies for hematological cancer applications | Gründer | - |
NovoTyr Therapeutics Ltd.
NovoTyr Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops insulin-like growth factor receptor inhibiitors | Gründer | - |
Quinova Rx Ltd.
Quinova Rx Ltd. Pharmaceuticals: MajorHealth Technology Develops cannabinoid quinone scaffold for antineoplastic therapy | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Institute for Advanced Studies In Aging & Geriatric Medi | |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology Is a biopharmaceuticals company | Health Technology |
TK-Signal Ltd.
TK-Signal Ltd. Medical SpecialtiesHealth Technology Develops therapies for hematological cancer applications | Health Technology |
NovoTyr Therapeutics Ltd.
NovoTyr Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops insulin-like growth factor receptor inhibiitors | Health Technology |
Quinova Rx Ltd.
Quinova Rx Ltd. Pharmaceuticals: MajorHealth Technology Develops cannabinoid quinone scaffold for antineoplastic therapy | Health Technology |
Israel Academy of Sciences & Humanities
Israel Academy of Sciences & Humanities Miscellaneous Commercial ServicesCommercial Services Operates as sciences and humanities academy | Commercial Services |
Targimmune Therapeutics AG
Targimmune Therapeutics AG BiotechnologyHealth Technology Develops novel targeted oncology immunotherapies | Health Technology |
















